University of Exeter spinout aiming to develop senotherapeutic interventions
SENISCA is a biotech spinout company from the University of Exeter, founded in 2020 and dedicated to the development of new approaches to reverse cellular senescence (senotherapeutics).
Our founders are world leaders in molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence. This innovation works by restoring the ability of cells to ‘fine tune’ the expression of their genes to rejuvenate aged cells.
At SENISCA, we are using this knowledge, concerning how and why cells become senescent, to develop a new generation of interventions, to turn back the ageing clock in old cells and to target the diseases and aesthetic signs of ageing. SENISCA interventions are small molecule or oligonucleotide-based.
Professor Lorna Harries - CSO (and co-founder)
Visit website: https://www.senisca.com/
See also: University of Exeter - UK university and member of the Russell Group of leading research-intensive UK universities
Mentioned in this Resource
People at SENISCA
Exeter's company SENISCA raises £2 million to treat age-related chronic diseases
University of Exeter - 09-Jun-2022
Funding might allow RNA-based rejuvenation tech to enter ex vivo lab testsRead more...
SENISCA to reverse senescence by targeting RNA splicing patterns
Longevity Technology - 08-Apr-2022
Lorna Harries details significant breakthroughs at fourth annual Longevity Leaders World CongressRead more...
SENISCA targets sensescence using a new ageing hallmark - dysregulated mRNA processing
Lifespan.io (LEAF) - 03-Nov-2021
Lorna Harries believes dysregulated splicing as a breakthrough senotherapeutic targetRead more...
SENISCA secures 1.3 million pounds to transform anti-ageing technology
University of Exeter - 12-Mar-2021
Spin out company from University of Exeter step forward towards precision medicine for age-related diseasesRead more...
LMC provides background and success outlook on 14 leading senolytic companies
Longevity Marketcap - 15-Dec-2020
Comprehensive review of companies' clinical and financial state of playRead more...
Nature Biotechnology reviews the state of play of senolytics
Nature Biotechnology - 12-Nov-2020
In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...Read more...
Taking the new path in the field of senolytics - SENISCA
Longevity Technology - 29-Jul-2020
Old cells will be more young and beautifulRead more...